Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 18Lymphoma, Non-Hodgkin 11Lymphoma, B-Cell 10Hematologic Diseases 7Lymphoma, Mantle-Cell 5Waldenstrom Macroglobulinemia 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 2Leukemia, Lymphoid 2Leukemia, B-Cell 2Syndrome 1Recurrence 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Dendritic Cell Sarcoma, Interdigitating 1Chromosome 17 deletion 1

Interventions

venetoclax 5pirtobrutinib 1obinutuzumab 1acalabrutinib 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Chromosome 17 deletion × pirtobrutinib × Clear all
NCT07342478 2026-05-14

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Newave Pharmaceutical Inc

Phase 3 Recruiting
306 enrolled
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡